NASDAQ
06.08.26 | 21:59
0,860 US-Dollar
-6,01 % -0,055
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | TELA Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| Di | TELA Bio names Heather Getz as CEO and Director | 1 | Seeking Alpha | ||
| TELA BIO Aktie jetzt für 0€ handeln | |||||
| Di | TELA Bio Names Heather Getz CEO | 2 | RTTNews | ||
| Di | TELA Bio appoints Heather Getz as chief executive officer | 1 | Investing.com | ||
| Di | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Di | TELA Bio, Inc.: TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director | 117 | GlobeNewswire (Europe) | MALVERN, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
| 20.07. | TELA Bio, Inc.: TELA Bio to Announce Second Quarter 2026 Financial Results | 2 | GlobeNewswire (USA) | ||
| 11.06. | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | TELA Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | Tela Bio verfehlt Q1-Prognosen: Aktie gibt nach | 1 | Investing.com Deutsch | ||
| 12.05. | TELA Bio Q1 2026 Earnings Call Transcript | 1 | Benzinga.com | ||
| 12.05. | TELA Bio GAAP EPS of -$0.21 misses by $0.02, revenue of $19.1M beats by $0.1M | 1 | Seeking Alpha | ||
| 12.05. | TELA Bio, Inc.: TELA Bio Reports First Quarter 2026 Financial Results | 194 | GlobeNewswire (Europe) | MALVERN, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen | |
| 12.05. | TELA Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.04. | TELA Bio, Inc.: TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues | 262 | GlobeNewswire (Europe) | MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen | |
| 21.04. | TELA Bio, Inc.: TELA Bio to Announce First Quarter 2026 Financial Results | 2 | GlobeNewswire (USA) | ||
| 27.03. | Citizens cuts Tela Bio stock price target on commercial transition | 2 | Investing.com | ||
| 25.03. | TELA Bio Analysts Cut Their Forecasts After Q4 Results | 1 | Benzinga.com | ||
| 25.03. | TELA Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 25.03. | TELA Bio, Inc. - 10-K, Annual Report | 1 | SEC Filings |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 46,700 | -4,10 % | Ihre wichtigsten Termine: Spannende Zahlen von: Sony, Moderna, AbbVie, Eaton, ExxonMobil, Linde und Puma! | © Foto: picture alliance / CFOTO | CFOTOGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 14,700 | +6,68 % | Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,036 | -7,67 % | PacBio Announces Second Quarter 2026 Financial Results | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent Business Highlights Total revenue of $39.0... ► Artikel lesen | |
| MYRIAD GENETICS | 2,750 | +0,66 % | Myriad Genetics, Inc.: Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability | Highlights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,085 | +1,40 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update | Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale API, long term non-clinical toxicology, completion of Phase 1b pharmacology, and new IP announcementsKing... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,770 | 0,00 % | Vir outlines ECLIPSE 1 top-line in Q4 2026 while projecting cash runway into the second half of 2028 | ||
| APOGEE THERAPEUTICS | 134,49 | +0,19 % | AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates | ||
| PRAXIS PRECISION MEDICINES | 369,91 | +15,88 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| QIAGEN | 36,140 | -0,63 % | Ihre wichtigsten Termine: Frische Zahlen von Ebay, Eli Lill, Allstate, Infineon, Novo Nordisk, Walt Disney | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 06:45 Uhr, Deutschland: Basler... ► Artikel lesen | |
| BRAVEHEART BIO | 30,290 | 0,00 % | Braveheart Bio, Inc.: Braveheart Bio Announces Pricing of Upsized Initial Public Offering | SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy... ► Artikel lesen | |
| ERASCA | 18,270 | -1,88 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| VERA THERAPEUTICS | 32,020 | +5,50 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| CREATIVE MEDICAL TECHNOLOGY | 1,160 | 0,00 % | Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz, CELZ-101 and CELZ-201 Diabetes Platforms | PHOENIX, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 26,400 | 0,00 % | Starke Zoryve-Umsätze: Guggenheim hebt Kursziel für Arcutis an | ||
| ENLIVEN THERAPEUTICS | 60,27 | +0,95 % | Guggenheim lowers Enliven Therapeutics stock price target to $78 |
TELA BIO INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,055 (-6,01 %) liegt der Kurs bei 0,860 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELA BIO INC finden Sie auf Wallstreet Online.